China-based Harbour BioMed (HKG: 2142) announced that its strategic partner NK Celltech, a company focusing on NK cell-based cell therapies, has successfully raised over RMB 100 million (USD 14.9 million) in a Series A financing round. The round was led by HUAGAI Capital, with participation from CAS Venture Capital, Qiandao Investment, Chengyi Capital, Sirius Capital, and Qiaojing Capital. The proceeds will be used for research and development of cell therapies. Following the financing, Harbour BioMed will become NK Celltech’s largest minority shareholder, excluding the founder team.
Company Background
NK Celltech was established in 2020 in Zhangjiang, Shanghai, with Harbour BioMed providing support for its founding and early operations. Harbour BioMed also transferred its human transgenic mouse platform technology in specific niche segments to NK Celltech, enabling the company to grow rapidly.-Fineline Info & Tech
